Skip to Main Content
Innovation

Innovation

Innovation to Impact: Dr. Lieping Chen and NextCure

Dr. Lieping Chen is a pioneer in the field of immuno-oncology and his discoveries have led to life-saving drugs for cancer patients. Now, with the support of the Yale Office of Cooperative Research, Dr. Chen has launched a startup—NextCure—that is poised to lead to even more breakthrough treatments.

Key Discoveries and Contributions

The Chen Lab works to understand the molecular, biochemical, and functional aspects of cell surface molecular pathways, including both costimulatory and coinhibitory molecules, in the control and modulation of immune responses. We are also interested in translating these laboratory findings into the development of new treatment options for cancer, autoimmune diseases, viral infections, transplantation rejection, and inflammation.

Characterizing New Co-Signaling Molecules and their Roles in the Regulation of an Immune Response

Key Publications

  • Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992 Dec 24;71(7):1093-102. PubMed PMID: 1335364.  
  • Chen L, Linsley PS, Hellström KE. Costimulation of T cells for tumor immunity. Immunol Today. 1993 Oct;14(10):483-6. PubMed PMID: 7506034.
  • Li Y, Hellstrom KE, Newby SA, Chen L. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J Exp Med. 1996 Feb 1;183(2):639-44. PubMed PMID: 8627175; PubMed Central PMCID: PMC2192440.  
  • Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013 Apr;13(4):227-42. PubMed PMID: 23470321; PubMed Central PMCID: PMC3786574